Ark Therapeutic (United States)

Recent papers from Ark Therapeutic (United States)

1. Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover StudyAdvances in Therapy · 2026
2. Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-OncologyCurrent Oncology Reports · 2026
3. VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trialThe Lancet Microbe · 2026
4. Cell-based second-generation immunotherapy BC1 in metastatic breast cancer.Journal of Clinical Oncology · 2026
5. Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.Journal of Clinical Oncology · 2026
6. Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.Journal of Clinical Oncology · 2026
7. A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)–targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
8. Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors.Journal of Clinical Oncology · 2026
9. Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.Journal of Clinical Oncology · 2026
10. Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.Journal of Clinical Oncology · 2026
11. Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.Journal of Clinical Oncology · 2026
12. Abstract 5132: Discovery and preclinical evaluation of a potent, orally bioavailable, highly selective, small molecule non-covalent KRAS[G12D] inhibitorCancer Research · 2026
13. Abstract 6701: Re-engineering cancer vaccines: Bria-OTS+ integrates innate and adaptive immunity for broad and persistent anti-tumor responsesCancer Research · 2026
14. Abstract 5392: Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202Cancer Research · 2026
15. Airborne ¹ O ₂ Delivery via a Superhydrophobic Dressing as a Pathway to Next‐Generation Wound Therapies, an in Vivo Murine Burn Model StudyAdvanced Healthcare Materials · 2026
16. DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy.2026
17. Topical mycophenolate for the treatment of uveitis-associated inflammationSHILAP Revista de lepidopterología · 2026
18. Abstract PS2-09-03: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancerClinical Cancer Research · 2026
19. Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplantAnnals of Hematology · 2026
20. A Novel SARS-CoV-2 mRNA Virus-Like Particle Vaccine is Highly Potent and Well Tolerated in Adults in a Phase I Randomized Clinical TrialOpen Forum Infectious Diseases · 2026